What’s Ahead for Achieve Life Sciences, Inc. (ACHV) After Reaching All-Time Low?

June 14, 2018 - By Christine McCrea

The stock of Achieve Life Sciences, Inc. (NASDAQ:ACHV) reached all time low today, Jun, 15 and still has $4.73 target or 9.00 % below today’s $5.20 share price. This indicates more downside for the $6.71 million company. This technical setup was reported by Barchart.com. If the $4.73 PT is reached, the company will be worth $604,080 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 25.18% or $1.75 during the last trading session, reaching $5.2. About 230,405 shares traded or 357.95% up from the average. Achieve Life Sciences, Inc. (NASDAQ:ACHV) has declined 74.49% since June 15, 2017 and is downtrending. It has underperformed by 87.06% the S&P500.

More important recent Achieve Life Sciences, Inc. (NASDAQ:ACHV) news were published by: Benzinga.com which released: “42 Stocks Moving In Thursday’s Mid-Day Session” on May 24, 2018, also Benzinga.com published article titled: “31 Stocks Moving In Thursday’s Mid-Day Session”, Benzinga.com published: “28 Stocks Moving In Wednesday’s Mid-Day Session” on June 06, 2018. More interesting news about Achieve Life Sciences, Inc. (NASDAQ:ACHV) was released by: Prnewswire.com and their article: “Achieve Life Sciences, Inc. Announces Reverse Stock Split” with publication date: May 23, 2018.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company has market cap of $6.71 million. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.